This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Health Discovery Corporation Applauds American Cancer Society’s Decision Against The Use Of The PSA For Routine Prostate Cancer Screening

Health Discovery Corporation (OTCBB: HDVY) announced today that it supports the American Cancer Society’s decision to issue new guidelines in the face of substantial data found in the largest prostate cancer studies ever conducted that were recently published in the New England Journal of Medicine in 2009. These published studies warned that using PSA to screen for prostate cancer doesn't necessarily save lives, and noted any benefits can come at a high price including over-diagnosis of prostate cancer leading to unnecessary treatments which can result in impotence and incontinence which are potentially devastating and life changing side effects in these men.

Health Discovery Corporation’s Science Advisory Board member, Dr. Thomas Stamey, the founder and former chairman of the Department of Urology at Stanford University Medical Center, and a world renowned leader in prostate cancer published in the Journal of Urology several years ago: “The era of the PSA is over.” At the time of Dr. Stamey's landmark publication, Health Discovery Corporation began the development of its new gene-based molecular diagnostic test for prostate cancer.

“Health Discovery Corporation’s new, urine-based 4-gene prostate cancer test which has been shown to have a 90% Sensitivity (for finding clinically significant, grade 3 or higher prostate cancer cells) and a 97% Specificity (for finding non-cancerous cells) was recently published in the peer-reviewed publication UroToday International,” said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “We are very pleased that the American Cancer Society is now warning men and their doctors about the risks of using the PSA test for routine prostate cancer screening," said Dr. Barnhill.

Health Discovery Corporation's new urine-based 4-gene prostate cancer test is licensed on a royalty based, worldwide co-exclusive basis to Quest Diagnostics Incorporated (NYSE: DGX) and Abbott (NYSE: ABT).

The Associate Press released a story today on the American Cancer Society’s new guidelines titled, “Cancer society stops urging docs to offer PSA test,” by Mike Stobbe, AP Medical Writer, and Stephanie Nano contributed to the story.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs